PHARMACOTHERAPEUTIC EVOLUTION OF ANTITUBERCULOSIS DRUG-A REVIEW
Journal Title: WORLD JOURNAL PHARMACY AND PHARMACEUTICAL SCIENCE - Year 2018, Vol 7, Issue 12
Abstract
Tuberculosis is a cosmopolitan human lung infection caused by Mycobacterium tuberculosis. It represents one of the main causes of death worldwide. The therapeutic management of this disease by antituberculosis drugs faces several obstacles such as low adherence, the long duration of treatment, adverse effects of the drugs and the existance of the latent tuberculosis caused by dormant bacilli. Furthermore, the drug treatment of co-infection HIV and tuberculosis resistant is in a situation of therapeutic deadlock. Therefore, it seemed worthwhile to make an inventory of antituberculosis drugs and have a better understanding of future therapeutic options. This study highlighted the existance of many "doubtful" non-drug treatments proposed to treat tuberculosis before the discovery of modern tuberculosis chemotherapy. Some of them suggested prayers, incantations (heal power of kings), or a simple rest combined with a balanced diet. Others less gentle methods such as the injection of air into the lungs recommended surgical treatments like thoracoplasty. Various treatment based on gold salts, cod liver oil or the sanatorium cures were also tested. The discovery of streptomycin in the 1940, was the beginning of the current anti-tuberculosis therapy. Indeed, research aimed at finding an alternative treatment, to overcome the Streptomycin resistance, led to the introduction in therapy of many other antituberculosis like Para-aminosalicylic acid (1944), Isoniazid (1952), the ethambutol (1957), Rifampicin (1967), the pyrazinamide (1980) and fluoroquinolones (1982). Moreover, in order to shorten the duration of treatment and to limit the the emergence and spread of resistance, combination of antituberculous drugs has been proposed and the treatment of tuberculosis has evolved from monotherapy to quadruple today. In addition, to deal with the appearance of poly-resistant strains and overcome the drawbacks existing tuberculosis drugs, research is underway to identify new biological targets and to develop antituberculosis of the future.
Authors and Affiliations
Ouattara Mahama
Keywords
Related Articles
- EP ID EP628184
- DOI -
- Views 160
- Downloads 0
SPECTROPHOTOMETRIC DETERMINATION AND CLOUD POINT EXTRACTION OF LAMOTRIGINE DRUG IN PURE FORM AND PHARMACEUTICAL PREPARATION
A new, simple and sensitive of two spectrophotometric methods for the determination of Lamotrigine drug has been developed. First method is based on diazotization of O-aminobenzoic acid, by sodium nitrite in acidic mediu...
FORMULATION AND EVALUATION OF NAPROXEN PROLIPOSOMAL GELS
The study was aimed to develop a proliposomal formulation for anti-inflammatory drug Naproxen. Proliposomes with various concentrations of mannitol, phospholipid and cholesterol were prepared using thin-film hydration te...
LIPID PEROXIDATION, ANTIOXIDANT PROFILE AND SOME BIOCHEMICAL PARAMETERS IN RAT APPLIED AMINOGLYCOZIDE
Amikacin were used for the treatment of infections caused by Gram (-) bacteria, have serious nephrotoxic and ototoxic side-effects. Effects of the amikacin administrated at therapeutic doses on blood lipid peroxidation,...
TRANSFUSION SUPPORT IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELLS: LITERATURE REVIEW
Hematopoietic stem cell transplantation is often the only cure for a patient. There are several obstacles that they face during the whole process of seeking a donor: the remission of the disease to enable the procedure,...
PHYTOCHEMICAL ANALYSIS, ANTIBACTERIAL AND ANTIOXIDANT ACTIVITY DETERMINATION OF MOMORDICA CHARANTIA
Momordica charantia is commonly known as bitter melon or bitter gourd, with Ayurveda name: karela.[1] It is found in the tropical and subtropical regions of the world, distributed in Asian countries and widely cultivated...